Out of 3867 papers identified, 106 were included. 5 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Out of 3867 papers identified, 106 were included. 5 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
ICU delirium is also associated with increased mortality and dementia in the longer term. 3 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
In older adults, trazodone is frequently prescribed for anxiety and insomnia owing to its perceived greater tolerability in comparison with benzodiazepines. 4 key findings →
Design: longitudinal study Participants: 123 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Dementia prevalence was 22%, with 35% undiagnosed. 4 key findings →
Design: prospective cohort Participants: 2,003 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The MAINTAIN intervention demonstrated high fidelity in home assessments and intervention delivery, with participants receiving a mean of 15 of the 22 available sessions with a range of 5-25 sessions. 5 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
An important goal of advance care planning (ACP) is ensuring that patients receive care concordant with their preferences. 5 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
SES and LA were associated with better cognitive performance at baseline, but were not associated with cognitive decline over time. 5 key findings →
Design: longitudinal study Participants: 181 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
In the Research Article "Magnitude and Time-Course of Dementia Risk in Stroke Survivors: A Population-Wide Matched Cohort Study" by Joundi et al., 1 the keys for Figure 3, A-D should indicate red for "Stroke," "Ischemic Stroke," "ICH," and "Stroke," respectively. 2 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Older adults with cognitive decline are vulnerable to various health problems. 2 key findings →
Design: randomized controlled trial Participants: 147 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Many individuals with advanced dementia die in hospital, despite preferring home death. 1 key finding →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
This preliminary report describes the development, reliability, and validity testing of the Geriatric Depression Scale (GDS) designed specifically for rating depression in the elderly. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Interrater reliability was high (median 0.98). 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Factors contributing to feelings of burden of caregivers of elderly persons with senile dementia were studied. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Eight thousand five hundred twenty-one articles were screened, and 75 articles were eligible to be included. 2 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
We replicated the CLU-MS4A4E interaction in a large case-control series and observed APOE ε4 and possible dominant effect. 1 key finding →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
This study aimed to identify lipid species associated with MPH response and explore lipid pathway disruptions in responders versus non-responders. 3 key findings →
Design: randomized controlled trial Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Two thousand three hundred and thirty two nonselected brains from 1- to 100-year-old individuals were examined using immunocytochemistry (AT8) and Gallyas silver staining for abnormal tau; immunocytochemistry (4G8) and Campbell-Switzer staining were used for the detection ofβ-amyloid.
Full summary, score breakdown and related studies → Original source Free full text
Amyloid deposition can be identified among cognitively normal elderly persons during life, and the prevalence of asymptomatic amyloid deposition may be similar to that of symptomatic amyloid deposition.
Full summary, score breakdown and related studies → Original source Free full text
Fibrillar amyloid-beta (Abeta) is found in the brains of many cognitively normal older people.
Full summary, score breakdown and related studies → Original source Free full text
This text describes the Alzheimer's Disease Neuroimaging Initiative, which addresses the growing incidence and socioeconomic impact of Alzheimer's disease as life expectancy increases.
Full summary, score breakdown and related studies → Original source Free full text
After 20 years follow-up of newly diagnosed patients with Parkinson's disease (PD), 100 of 136 (74%) have died.
Full summary, score breakdown and related studies → Original source Free full text
Plasma pTau181 may have utility as a biomarker of AD pathophysiology and as a noninvasive screener for elevated brain Aβ.
Full summary, score breakdown and related studies → Original source Free full text
With the increasing life expectancy in developed countries, the incidence of Alzheimer's disease (AD) and thus its socioeconomic impact are growing.
Full summary, score breakdown and related studies → Original source Free full text
In Alzheimer’s disease (AD), β-amyloid (Aβ) plaques are tightly enveloped by microglia processes, but the significance of this phenomenon is unknown.
Full summary, score breakdown and related studies → Original source Free full text
We present a new ARWMC scale applicable to both CT and MRI that has almost equal sensitivity, except for certain regions.
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →